Clinical Trials Logo

Filter by:
NCT ID: NCT05518201 Completed - Anal Cancer Clinical Trials

Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

Start date: September 23, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.

NCT ID: NCT05518136 Completed - Infant Development Clinical Trials

Evaluations of Cardiopulmonary Function and Motor Development of Congenital Heart Disease

Start date: April 10, 2021
Phase: N/A
Study type: Interventional

In this single-center, randomized controlled trial, patients (4-8 months) with CHD were randomly assigned to either a recovery group (home-based rehab exercise periodically) supervised by cellphone APP or to a control group. Left ventricular ejection fractions (LVEF), the rate of increase in heart rate (rHRI), and the rate of recovery heart rate (rHRR) were measured for representing cardiopulmonary capacity. The Alberta test and Neuro-intelligence Scale were used to evaluate their motor developmental outcomes. This study verified the feasibility of this rehab method and indicated that 6-month home-based exercise training can improve cardiopulmonary endurance and motor developmental level in infant CHD patients.

NCT ID: NCT05517681 Completed - Indocyanine Green Clinical Trials

Application of ICG in Lymph Node Dissection During Radical Resection of Rectal Cancer With Preserved Autonomic Nerves Around LCA and IMA

Start date: September 7, 2020
Phase: N/A
Study type: Interventional

Indocyanine green NIR imaging is valuable for lymph node dissection in D3 radical surgery for rectal cancer. It can guide the intraoperative improvement of lymph node dissection based on the preservation of LCA and peripheral autonomic nerves of IMA. This not only reduces the occurrence of postoperative complications and promotes rapid postoperative recovery, but also provides a more precise and individualized comprehensive treatment plan for patients after surgery. In addition,this trial also demonstrated that ICG is safe and feasible for use in rectal cancer

NCT ID: NCT05517616 Completed - Pharmacokinetics Clinical Trials

The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects

Start date: September 14, 2022
Phase: Phase 1
Study type: Interventional

This study is a single-center, open-label, single-dose clinical pharmacokinetic study. The purpose of this study is to investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose of 400mg, 200μCi [14C] APG-2575 to healthy subjects.

NCT ID: NCT05517148 Completed - Stress Clinical Trials

Effects of an Immersive Virtual Reality Intervention Combined With Mindfulness-based Stress Reduction

Start date: September 25, 2022
Phase: N/A
Study type: Interventional

Mindfulness-based stress reduction (MBSR), a widely used method to improve mental state and sleep quality, was developed by Kabat-Zinn in 1970. The meditation of MBSR is effective in regulating patients' emotions, leading to reduced stress, pain, and psychological symptoms. Studies have demonstrated that MBSR has a positive impact on multiple psychological and physical symptoms in a variety of cancers. On this basis, investigators found that VR treatment can also help patients relax, and it has been widely used in cancer symptom relief in recent years. VR treatment involves using headset devices that fully restrict the vision field to content displayed inside the headset screen; As a treatment modality, VR provides a unique environment comprising 3D visually immersive experiences that are enriched with stereo sounds and elements such as rich colors and scenic environments that enhance elicitation of desired states of arousal and affect. Within the therapeutic context, VR may be flexibly designed and tailored to address the needs of specific conditions (eg, anxiety, depression, pain) auditory perception is not fully restricted, though the corresponding device-delivered auditory content commands attention.

NCT ID: NCT05516329 Completed - Prostate Cancer Clinical Trials

Study of 18F-Thretide PET/CT in Patients With Prostate Cancer

Start date: August 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the diagnostic performance and safety of 18F-Thretide PET/CT in patients with biopsy proven prostate cancer who has no any form of therapy against prostate caner or suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.

NCT ID: NCT05515471 Completed - Clinical trials for Treatment of Dry Eye Disease With Meibomian Gland Dysfunction

Effect of SHR8058 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction

Start date: February 4, 2021
Phase: Phase 3
Study type: Interventional

The study is being conducted to evaluate the efficacy and safety of SHR8058 eye drops for patients with dry eye disease.

NCT ID: NCT05515458 Completed - Renal Impairment Clinical Trials

Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function

Start date: November 20, 2022
Phase: Phase 1
Study type: Interventional

This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with renal impairment compared to subjects with normal renal function.

NCT ID: NCT05515445 Completed - Hepatic Impairment Clinical Trials

Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

Start date: December 3, 2022
Phase: Phase 1
Study type: Interventional

This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with varying degrees of hepatic impairment compared to subjects with normal hepatic function.

NCT ID: NCT05512832 Completed - In-stent Restenosis Clinical Trials

In-stent Restenosis and Pericoronary Fat Attenuation Index

Start date: January 1, 2020
Phase:
Study type: Observational

This study aims to investigate the predictive value of fat attenuation index (FAI) and related radiomics characteristics of pericoronary fat in patients after percutaneous coronary intervention (PCI) for the occurrence of in-stent restenosis (ISR) during the follow-up period (9 to 24 months). The results of this study are expected to provide an early assessment of the inflammation around the coronary lesion segment in patients after PCI, and provide a basis for early targeted intensive drug therapy in clinical practice.